AI Terminal
ABIVAX
Interim / Quarterly Report • Sep 30, 2021
1063_rns_2021-09-30_c3d47620-2e84-4a92-92e6-1752758bd682.html
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
News Details
Corporate | 30 September 2021 18:00
Abivax announces the release of its 2021 half-year financial report
DGAP-News: ABIVAX / Key word(s): Half Year Report
30.09.2021 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax announces the release of its 2021 half-year financial report
PARIS, France, September 30, 2021 – 6:00 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report. This document is available in electronic version on the website of the company ( www.abivax.com – “Investors” ) and on the website of the French financial markets authority, AMF ( www.amf-france.org ).
*****
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.
Contacts
| Abivax Communications Regina Jehle [email protected] +33 6 24 50 69 63 |
Investors LifeSci Advisors Ligia Vela-Reid [email protected] +44 7413 825310 |
Press Relations & Investors Europe MC Services AG Anne Hennecke [email protected] +49 211 529 252 22 |
| Public Relations France Actifin Ghislaine Gasparetto [email protected] +33 6 21 10 49 24 |
Public Relations France DGM Conseil Thomas Roborel de Climens [email protected] +33 6 14 50 15 84 |
Public Relations USA Rooney Partners LLC Jeanene Timberlake [email protected] +1 646 770 8858 |
30.09.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de